Breaking News

NImmune Acquires Development & Commercialization Rights for Omilancor in Asia

Omilancor is a once-daily, oral therapy in Phase 3 clinical development for ulcerative colitis and Phase 2 for Crohn’s disease, with multiple I&I indications pl

Author Image

By: Charlie Sternberg

Associate Editor

NImmune Biopharma, a private late-clinical-stage precision inflammation and immunology (I&I) biopharmaceutical company, has acquired development and commercialization rights for omilancor in Asia. Covered markets include China, Macau, Hong Kong, Taiwan, Thailand, Singapore, South Korea, Cambodia, Indonesia, Myanmar, the Philippines, Thailand, and Vietnam.   Upon closing of this transaction, NImmune will wholly own global rights to omilancor and the entire LANCL2 portfolio of immunoregulato...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters